Compumedics Posts $63.4M Sales Orders, EBITDA Returns to $3M in FY25

A Breakout Year for Compumedics

Compumedics Limited (ASX, CMP) has delivered a standout FY25 performance, marking a strategic inflection point for the medical device company. The firm reported record sales orders of $63.4 million, a 22% increase over the prior year, alongside a return to profitability with an EBITDA of approximately $3 million. This turnaround reflects disciplined cost management and a shift towards higher-margin, recurring revenue streams.

Driving Growth, US Market and SaaS Expansion

The US market emerged as a powerhouse for Compumedics, with sales orders soaring 115% year-on-year. Particularly notable was the Sleep Diagnostics segment, which grew 39% overall, led by a doubling of US Sleep Diagnostics orders to $23.5 million. Meanwhile, the company’s SaaS offerings, including Somfit and Nexus 360, saw revenue jump 41%, with US Somfit sales orders exploding by 675% to $3.1 million. This rapid SaaS growth underscores Compumedics’ successful pivot to connected health platforms.

Product Innovation and MEG System Prospects

Compumedics is also advancing its product pipeline with the upcoming launch of Somfit D, a disposable device targeting the substantial US Home Sleep Test market estimated at 3-4 million units annually. Additionally, the company has three Magnetoencephalography (MEG) systems in progress, expected to generate around $15 million in revenue in FY26. Expansion into the paediatric MEG market and growing demand in China further enhance the company’s growth outlook.

Outlook and Strategic Focus

Looking ahead, Compumedics reaffirmed its FY26 guidance, targeting at least $70 million in revenue and approximately $9 million in EBITDA. SaaS and connected platforms are expected to contribute over 20% of group revenue, delivering scalable, high-margin returns. Executive Chairman Dr. David Burton highlighted the company’s transition to a more focused, cash-generative global business model, driven by recurring revenues and clinical innovation.

While the FY25 results are unaudited and EBITDA is subject to final audit, the momentum is clear. Compumedics is leveraging its international footprint, including strong growth in Asia (up 71%) and Europe (up 12%), to build a diversified and resilient business.